Myocardial Protection of Exenatide in AMI

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Experimental evidence suggests exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in various conditions. The investigators examined whether conventional use of exenatide at the time of primary percutaneous coronary intervention would reduce the infarct size in patients with ST-segment elevation myocardial infarction (STEMI).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyunghee University Medical Center
• Treatments: Exenatide; Islet Amyloid Polypeptide; Polystyrene sulfonic acid

Criteria

Inclusion Criteria:

• age between 20 and 79 years

• patients presenting with first ST-segment elevation myocardial infarction

• Thrombolysis in Myocardial Infarction [TIMI] flow grade 0)

Exclusion Criteria:

• cardiac arrest

• ventricular fibrillation

• cardiogenic shock

• hemodynamic instability

• suspicious stent thrombosis

• left bundle branch block

• previous acute myocardial infarction

• previous coronary artery bypass operation

• significant valvular heart disease

• primary myocardial disease

• atrial fibrillation

• significant hepatic or renal dysfunction, hypoglycaemia,

• diabetic ketoacidosis

• active infection or chronic inflammatory disease

• malignancy

• women who were pregnant or who were of childbearing age